{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:37:16Z","timestamp":1785418636828,"version":"3.56.0"},"reference-count":33,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 diabetes (T2D) and obesity increase individuals\u2019 risk of microvascular and macrovascular complications, which may increase healthcare costs. The RESET program combined low-calorie diet using diabetes-specific nutritional formula and a digital lifestyle behavior change program to target sustainable weight loss and improved diabetes management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To quantify projected changes in diabetes-related complication risks following the 12-week weight-loss phase of the RESET program and to relate these modeled risk reductions to program costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from 157 adults with type 2 diabetes (mean age, 56 years; diabetes duration, 2.2 years; baseline body mass index (BMI), 35 kg\/m\u00b2; HbA1c, 7.5%) completing the RESET weight-loss phase were analyzed. Observed mean changes in HbA1c, BMI, and systolic blood pressure were applied to the UK Prospective Diabetes Study Outcomes Model 2 (UKPDS-OM2) to estimate projected relative risk reductions in microvascular and macrovascular complications over a 3-month horizon. Program costs were derived using a microcosting approach from the healthcare payer perspective, and parameter uncertainty was evaluated through 20\u2009000 Monte Carlo simulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants achieved mean reductions of 1.0% in HbA1c, 11.0 kg in body weight, and 4.5 mmHg in systolic blood pressure. The model projected an overall relative reduction in total complication risk of 15.4% (95% confidence interval [CI], 9.1-21.4), corresponding to an absolute reduction of 1.9 projected events per 1000 participants over 3 months, comprising a \u201313.2% mean reduction in macrovascular and \u201323.8% in microvascular complication risks. Mean program cost was \u00a31236 per participant (95% CI, \u00a31001-\u00a31492), corresponding to an incremental cost of \u00a384 per 1% relative risk reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short-term, intensive weight loss achieved clinically meaningful improvements in HbA1c and body weight that were associated with favorable reductions in projected microvascular and macrovascular complications at modest cost. Absolute event reductions over 3 months were modest, and sustaining these improvements is essential to realize long-term clinical and economic benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.162856","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:12:22Z","timestamp":1781637142000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":0,"title":["Projected Reduction of Diabetes- and Obesity-Related Complication Risks Following the 12-Week Weight-Loss Phase of the RESET Study"],"prefix":"10.36469","volume":"13","author":[{"given":"Bjoern","family":"Schwander","sequence":"first","affiliation":[{"name":"AHEAD GmbH, Bietigheim-Bissingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8777-4775","authenticated-orcid":true,"given":"Kirk W.","family":"Kerr","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00p99t114","id-type":"ROR","asserted-by":"publisher"}],"name":"Abbott Nutrition, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rueda","sequence":"additional","affiliation":[{"name":"Abbott Nutrition, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Camprubi-Robles","sequence":"additional","affiliation":[{"name":"Abbott Nutrition, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Northway","sequence":"additional","affiliation":[{"name":"Changing Health Ltd., London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Lumsden","sequence":"additional","affiliation":[{"name":"Changing Health Ltd., London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Taylor","sequence":"additional","affiliation":[{"name":"Changing Health Ltd., London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suela","family":"Sulo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00p99t114","id-type":"ROR","asserted-by":"publisher"}],"name":"Abbott Nutrition, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","article-title":"UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82","volume":"56","author":"A. J. Hayes","year":"2013","journal-title":"Diabetologia"},{"key":"ref2","article-title":"Type 2 diabetes in adults - management (update): methods, evidence and recommendations for health economic modelling","author":"National Institute for Health and Care Excellence (NICE)"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40273-023-01312-4","article-title":"A systematic review of methodologies used in models of the treatment of diabetes mellitus","volume":"42","author":"M. Antoniou","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"ref4","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1185\/03007995.2010.494451","article-title":"Economic models in type 2 diabetes","volume":"26","author":"Y. Yi","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"suppl 1","key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/db24-1836-LB","article-title":"1836-LB: Real-world impact of a remote, digitally enabled lifestyle program with diabetes-specific formula as part of low-calorie diet among people with obesity and type 2 diabetes\u2014the RESET Study","volume":"73","author":"M. Trenell","year":"2024","journal-title":"Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/cd25-0054","article-title":"A pathway to type 2 diabetes remission weight reduction and blood glucose improvements are facilitated by a low-calorie diet including diabetes-specific nutritional formula and the use of digitally-enabled reinforcement","author":"M. Trenell","year":"2025","journal-title":"Clinical Diabetes"},{"issue":"10","key":"ref7","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","article-title":"A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)","volume":"47","author":"P. M. Clarke","year":"2004","journal-title":"Diabetologia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12962-015-0038-8","article-title":"Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model","volume":"13","author":"P. McEwan","year":"2015","journal-title":"Cost Eff Resour Alloc"},{"issue":"7","key":"ref9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2337\/diacare.24.7.1167","article-title":"Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55)","volume":"24","author":"T. M. Davis","year":"2001","journal-title":"Diabetes Care"},{"issue":"10","key":"ref10","doi-asserted-by":"publisher","first-page":"e14656","DOI":"10.1111\/dme.14656","article-title":"Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)","volume":"38","author":"J. Leal","year":"2021","journal-title":"Diabet Med"},{"issue":"10397","key":"ref11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"K. L. Ong","year":"2023","journal-title":"Lancet"},{"issue":"7160","key":"ref12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"5","key":"ref13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"M. E. J. Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s2213-8587(23)00385-6","article-title":"5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study","volume":"12","author":"M. E. Lean","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"ref15","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/archinternmed.2010.334","article-title":"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial","volume":"170","author":"R. R. Wing","year":"2010","journal-title":"Arch Intern Med"},{"issue":"7258","key":"ref16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"I. M. Stratton","year":"2000","journal-title":"BMJ"},{"issue":"9","key":"ref17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa0908359","article-title":"Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults","volume":"362","author":"E. Selvin","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"ref18","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"R. R. Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"ref19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"R. R. Wing","year":"2011","journal-title":"Diabetes Care"},{"issue":"2","key":"ref20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jval.2014.12.004","article-title":"Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence","volume":"18","author":"Y. Zhong","year":"2015","journal-title":"Value Health"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198529446.001.0001","article-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"M. Drummond","year":"2005","edition":"3"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1515797","article-title":"Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021","volume":"13","author":"X. Huang","year":"2025","journal-title":"Front Public Health"},{"issue":"12","key":"ref23","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40273-015-0309-4","article-title":"Dealing with time in health economic evaluation: methodological issues and recommendations for practice","volume":"33","author":"J. F. O'Mahony","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40273-020-00922-6","article-title":"Comparing the cohort and micro-simulation modeling approaches in cost-effectiveness modeling of type 2 diabetes mellitus: a case study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM","volume":"38","author":"M. Willis","year":"2020","journal-title":"PharmacoEconomics"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study","volume":"22","author":"Look AHEAD investigators","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"ref26","article-title":"Type 2 diabetes in adults: management (NICE guideline NG28)","author":"National Institute for Health and Care Excellence (NICE)"},{"issue":"3","key":"ref27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s13300-024-01530-9","article-title":"Therapeutic inertia in the management of type 2 diabetes: a narrative review","volume":"15","author":"P. Rodriguez","year":"2024","journal-title":"Diabetes Ther"},{"issue":"1","key":"ref28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40842-023-00160-7","article-title":"Predictors of lack of glycemic control in persons with type 2 diabetes","volume":"10","author":"J. Z. Louie","year":"2024","journal-title":"Clin Diabetes Endocrinol"},{"issue":"23","key":"ref29","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1001\/jama.2012.67929","article-title":"Association of an Intensive lifestyle intervention with remission of type 2 diabetes","volume":"308","author":"E. W. Gregg","year":"2012","journal-title":"JAMA"},{"issue":"10120","key":"ref30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"M. E. Lean","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"ref31","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","article-title":"Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol","volume":"54","author":"E. L. Lim","year":"2011","journal-title":"Diabetologia"},{"issue":"9131","key":"ref32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"ref33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/BF00400195","article-title":"UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance","volume":"34","author":"UKPDS investigators","year":"1991","journal-title":"Diabetologia"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/162856-projected-reduction-of-diabetes-and-obesity-related-complication-risks-following-the-12-week-weight-loss-phase-of-the-reset-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:12:24Z","timestamp":1781637144000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/162856-projected-reduction-of-diabetes-and-obesity-related-complication-risks-following-the-12-week-weight-loss-phase-of-the-reset-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.162856","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}